POMDOCTOR Receives Nasdaq Delisting Notice for Sub-$1.00 Bid Price

summarizeSummary

POMDOCTOR Ltd. announced it received a Nasdaq deficiency letter for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period to avoid potential delisting.

check_boxKey Events

• Nasdaq Deficiency Notice Received

  POMDOCTOR Ltd. received a written notification from Nasdaq's Listing Qualifications Department on January 29, 2026, indicating non-compliance with the minimum bid price rule.

• Failure to Meet Minimum Bid Price

  The company's American depositary shares (ADSs) closed below the US$1.00 minimum bid price requirement for 33 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).

• 180-Day Compliance Period Granted

  POMDOCTOR has been granted a 180-calendar day period, until July 28, 2026, to regain compliance. The stock must close at or above $1.00 for a minimum of ten consecutive business days.

• No Immediate Effect on Listing

  The deficiency letter has no current effect on the listing or trading of the company's ADSs on Nasdaq, but failure to comply by the deadline could lead to delisting.

auto_awesomeAnalysis

POMDOCTOR Ltd. has received a formal notification from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement. This is a critical development as it puts the company's Nasdaq listing at risk. While the company has a 180-day compliance period, regaining compliance will require a significant increase in its stock price, which currently trades at $0.2464. Failure to comply could lead to delisting, severely impacting liquidity and investor confidence. This negative news overshadows the recent positive announcement on January 16, 2026, regarding the expansion of its internet hospital business through strategic partnerships, as the company's ability to maintain its public listing is now a primary concern.